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Hypoxia, the result of an inadequacy between a disorganized and functionally impaired
vasculature and the metabolic demand of tumor cells, is a feature of glioblastoma.
Hypoxia promotes the aggressiveness of these tumors and, equally, negatively correlates
with a decrease in outcome. Tools to characterize oxygen status are essential for the
therapeutic management of patients with glioblastoma (i) to refine prognosis, (ii) to adapt
the treatment regimen, and (iii) to assess the therapeutic efficacy. While methods that are
focal and invasive in nature are of limited use, non-invasive imaging technologies have
been developed. Each of these technologies is characterized by its singular advantages
and limitations in terms of oxygenation status in glioblastoma. The aim of this short
review is, first, to focus on the interest to characterize hypoxia for a better therapeutic
management of patients and, second, to discuss recent and pertinent approaches for
the assessment of oxygenation/hypoxia and their direct implication for patient care.
Keywords: hypoxia, glioblastoma, MRI, PET, multimodal imaging
Hypoxia and Glioblastoma
As an aggressive solid tumor, glioblastoma (GBM) presents cardinal histological features of chaotic
microvascular proliferation and necrotic foci. However, the neoangiogenesis is dysfunctional and
normal tissue oxygen tension is not maintained (1). The resulting imbalance between oxygen
consumption and supply is called hypoxia. An important spatial heterogeneity is observed in
GBM with severely hypoxic zones and peripheral infiltration accompanied by a microvascular
proliferation (2). GBM cells, in hypoxic conditions, express transcriptional factors, such as the
hypoxia-inducible factor (HIF), which, by the induction of various gene expressions, is involved in
tumor cell adaptation. Hypoxia plays a pivotal role in the spread of tumor cells and, hence, invasion
(3). Hypoxia is also a key factor in the rapaciousness of human GBM and the characterization of
hypoxia discriminates poor from long outcomes (4). Moreover, hypoxia greatly impacts therapeutic
efficacy. For instance, it is known that the degree of oxygenation is critical for the efficacy of
both radiation therapy and chemotherapy (5). All these aspects are summarized in Figure 1.
Abbreviations: BLI, bioluminescence imaging; EPR, electron paramagnetic resonance; GBM, glioblastoma; HB, hemoglobin;
HIF, hypoxia-inducible factor; MRI, magnetic resonance imaging; NIRS, near infrared spectroscopy; PET, positron emission
tomography; ptO2, tissular oxygen pressure; SO2, oxygen saturation.
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FIGURE 1 | Schematic representation of the negative role of hypoxia in
tumor growth and therapeutic response in glioblastoma. The growth of a
GBM is a feed-forward (vicious) cycle exacerbated by hypoxia as depicted in
red. Hypoxia renders the tumor less susceptible to standard chemo-(CT) and
radio-therapy (X-ray) as shown in blue. Future treatment strategies are indicated
in purple.
Hence, the assessment of tissue oxygen tension in GBM is crucial
to personalize the treatment for each patient and to monitor its
efficacy. Various methods, more or less invasive (Table 1), have
been developed to assess the level of oxygenation at different
compartments ranging from blood to cells.
Identification of Hypoxia at the Molecular
Scale: Immunohistochemistry
Evaluation of hypoxia at the molecular scale can be performed
by the detection of hypoxia-activated endogenous molecules,
such as HIFα, and its targets, such as CAIX, Glut1, and VEGF.
Another approach is to detect pimonidazole uptake in cells after
systemic administration prior to biopsy. Immunohistochemistry
has demonstrated its usefulness in the classification of GBM
patients as a function of the level of hypoxia within the tumor and
then predict recurrence and overall survival (4). The limitation
to this technique is its invasive nature and the approach is
restricted to a small biopsy, which may be not representative of
the entire tumoral mass. Ideally and given the temporo-spatial
heterogeneity of GBM, a method able to continuously and
repeatedly assess hypoxia by three-dimensional imaging would
be more than desirable.
Assessment of Local Tissue Oxygenation:
Intracerebral Probes
The most direct assessment of tissue oxygenation is to measure
the regional tissular oxygen pressure (ptO2) by probes implanted
directly into the brain. The first probe developed was the Eppen-
dorf polarographic ptO2 electrode, which relies on the measure-
ment of the current generated at a cathode coated with thin gold
by ionization of oxygen at  700mV. The needle is mounted on a
stepping motor that sequentially advances and retracts the needle
tip. This approach allows the creation of a histogram of ptO2
recorded from the tissue of interest. The temporal assessment
of ptO2 is possible but the electrochemical reduction reduces
the dissolved oxygen causing a continuous signal decrease with
time. A second probe, more recently used, is the OxyLite™ probe
(Oxford-Optronix). Light pulses carried by an optical fiber induce
pulsatile fluorescence of a ruthenium luminophore incorporated
into a silicone rubber polymer at the probe tip. The lifetime of
the fluorescent pulses is inversely proportional to the oxygen
tension in the tip. In a syngeneicmodel of rhabdomyosarcoma, the
sensitivity of this method was exemplified by a real-time variation
of tumor ptO2 during induced hypercapnia (6).
Despite the fact that oxygen sensitive probes allow a direct
assessment of ptO2, their major limitation is that they only allow a
focalmeasurement ofO2 tensions. It is not possible to ascertain the
exact location of the probe, e.g., in a necrotic or a peripheral area
of the tumor. A second disadvantage is the invasiveness of these
probes, which are unlikely to have clinical applications. Finally,
there is also the fact that histography consumes oxygen.
Assessment of Hypoxia in Glioblastoma
with Imaging
Several imaging methods have been developed to assess oxygen
status in GBM patients but two main approaches are widely
employed and based on MRI and PET technologies. These
methods evaluate the level of oxygen in different physiological
compartments: blood vessels (oxygen saturation, SO2), tissue
(ptO2), or cellular level and can thus render directly or indirectly
indices of oxygenation.
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TABLE 1 |Methodological approaches to evaluate oxygenation in glioblastoma: advantages and limitations.
Advantages Limitations
Immunohistochemistry Routinely performed in neuropathology labs Indirect assessment of ptO2
Invasive and localized
Probes Direct and quantitative assessment of ptO2 Invasive and localized
Low reproducibility
Consumption of oxygen (for Eppendorf probes)
NIRS Setup and application in clinical routine are easy Indirect assessment of ptO2
No contrast agent injection Superficial and regional
qBOLD Setup and application in clinical routine are easy Indirect assessment of ptO2
Whole brain characterization Specificity for hypoxia needs to be validated
Sensitive
[19F]-MRI Direct and quantitative assessment of ptO2 Needs contrast agent injection potentially toxic
Needs 19F coil (not easy for clinic application)
Relatively low spatial resolution
EPR imaging Direct and quantitative assessment of ptO2 Localized (for EPR)
Whole brain characterization Very low spatial resolution
No studies in brain tumors
MOBILE Whole brain characterization Indirect and relative assessment of ptO2
No studies in brain tumors
Bioluminescence imaging Indicator of cellular hypoxia Needs genetically engineered tumor cells
Not applicable for patients
15Oxygen Whole brain characterization Administration of a gaseous radioactive contrast agent
No linear relation between oxygen consumption and cellular hypoxia
[62Cu]/[64Cu]-ATSM Characterization of moderate hypoxia Injection of a radioactive contrast agent
Whole brain characterization Long half-life (12.7 h)
Specificity for hypoxia is discussed
[18F]-FMISO Indicator of cellular hypoxia Injection of a radioactive contrast agent
Particularly adapted to radiation therapy modulation Relative long time before steady-state acquisition (2 h)
Whole brain characterization
[18F]-FAZA Indicator of cellular hypoxia Injection of a radioactive contrast agent
More rapid clearance than [18F]-FMISO Needs to be validated in a greater number of studies
Whole brain characterization
[18F]-HX4 and [18F]-FETNIM Indicator of cellular hypoxia Injection of a radioactive contrast agent
Whole brain characterization Not recommended for brain tumors
[18F]-EF5 Indicator of cellular hypoxia Injection of a radioactive contrast agent
Sensitivity near to immunohistochemistry Synthesis of radiotracer remains difficult
Whole brain characterization
[18F]-RP-170 Reflect of cellular hypoxia Injection of a radioactive contrast agent
Whole brain characterization Needs to be validated in a greater number of studies
Estimation of Tumor Hypoxia in the
Vascular Compartment: NIRS and
BOLD-MRI
Near Infrared Spectroscopy
Near infrared spectroscopy (NIRS) is a simple, non-invasive but
indirect method to characterize the level of oxygenation in blood.
Hemoglobin (Hb) has an important photon absorption level in the
near infrared range. The absorption spectrum is different if the
hemoglobin is fully oxygenated or fully deoxygenated (deoxyHb).
NIRS is able to characterize the concentration of the different
forms of hemoglobin to reflect oxygen saturation (7). However,
the NIRS characterization is superficial and is only reliable to a
depth of 3–5mm in the adult.
Blood Oxygen Level-Dependent MRI
Blood oxygen level-dependent MRI (BOLD-MRI) is a tomo-
graphic approach to detect changes in paramagnetic deoxyHb.
From the complex relationship between T2* and the Hb/deoxyHb
ratio, a method to measure the SO2 has been developed and
termed as qBOLD-MRI where “q” stands for quantitative. The
relationship between the T2* signal and SO2 is multifactorial and
depends on several parameters, such as cerebral blood volume
(CBV), local hematocrit, T2 value, B0 field, and oxygen saturation
(8). With the quantification and integration of these parameters,
a SO2 map can be obtained. At a preclinical level, Christen and
colleagues (8) have demonstrated the sensitivity of this method
to detect changes not only in brain oxygenation during hypox-
emia episodes but also in murine orthotopic models of GBM (9).
Given that anatomical MRI is in use routinely, additional scan
time to characterize tumor hypoxia by qBOLD-MRI could yield
meaningful clinical data. The ready accessibility of MRI tempts
one to use BOLD-MRI to assess hypoxia. However, BOLD-MRI,
entirely focused on the vascular compartment (SO2), corresponds
to an indirect assessment of oxygenation in tissue. While the use
of qBOLD-MRI corrects some pitfalls in the standard BOLD-MRI
technique (10), the specificity of this approach for hypoxia still
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requires validation. Indeed, SO2 and ptO2 are non-linear and
various parameters affect the sigmoid shape of the relationship
between the two parameters. Nonetheless, the extrapolation of
ptO2 from SO2 is feasible under physiological circumstances, it
is highly critical in a tumoral environment with several disturbed
metabolic processes.
Imaging of Oxygenation in the Tissue
Compartment: 19F-MRI and EPRI
[19F]-MRI
The relaxivity (R1) of contrast agents saturated with 19fluorine
(such as perfluorocarbons or hexafluorobenzene administered
either intravenously or directly in the brain tissue) is directly
proportional to ptO2. In a murine GBM model, Lemaire and
colleagues (11) have shown the ability of [19F]-MRI to charac-
terize the difference of tumor oxygenation between basal con-
ditions (ptO2 10mmHg) and during inhalation of 100% oxy-
gen (ptO2 170mmHg). Although [19F]-MRI is quantitative, this
approach is limited by the potential toxicity of the tracer.
Electron Paramagnetic Resonance Imaging
Electron paramagnetic resonance (EPR) specifically responds
only to atoms ormolecules with unpaired electrons, including free
radicals, free electrons, and some valence states of metal ions. The
phenomenon that is observed with EPR is the transition (reso-
nance absorption of energy) between the two energy states that
can occur in an unpaired electron systemplacedwithin amagnetic
field. This field separates the energy states associated with the
two possible spin states of unpaired electrons. The presence of
other unpaired electron species can affect the EPR spectrum.
Molecular oxygen, with two unpaired electrons, can be detected
either directly by EPR at ambient conditions due to fast relaxation
of spins or detected indirectly from the oxygen-induced changes
in the EPR spectrum of other paramagnetic probes in the system.
From oxygen-induced EPR line bandwidth, one can quantify the
oxygen concentration (12), in a preclinical study, have shown the
ability and repeatability of electron paramagnetic resonance imag-
ing (EPRI) to evaluate the different levels of oxygen in four brain
tumormodels. Furthermore, EPRI permits a spatial localization of
ptO2 (13). However, because the signal is weak in EPRI, the slice
thickness is important and the spatial resolution relatively low.
Assessment of Oxygenation at the Cellular
Level: MOBILE and BLI
Mapping of Oxygen by Imaging Lipid relaxation
Enhancement-MRI
Because oxygen is 11 times more soluble in lipids than in water,
it has been proposed to measure T1 relaxivity in lipids for the
assessment of oxygen status (14). With GBM, this method holds
promise given that the cerebral concentration of phospholipids is
important in the brain. However, even if this method is sensitive
to changes in ptO2 during gas inhalation, for example, studies in
brain tumors have yet to be performed.
Bioluminescence Imaging
Bioluminescence imaging (BLI) is based on the detection of light
emitted by cells expressing a luciferase gene under the control
of a hypoxia-sensitive promoter containing hypoxia response
elements (HRE) sequences, has been advanced to measure
brain hypoxia. An engineered human GBM cell line expressing
luciferase under the control of HRE was implanted orthotopically
and well correlated with other hypoxic reporters (15). Nonethe-
less, BLI has a low-spatial resolution and the tumoral hetero-
geneity will be difficult to assess and no translation to man is
feasible.
Assessment of Hypoxia with PET
15Oxygen
The first PET radiotracer, used to assess oxygen levels in brain, was
the positron emitter 15Oxygen which allowed several validated
quantitative methods to map cerebral blood flow (CBF), CBV,
oxygen extraction fraction (OEF), and the cerebral metabolic rate
of oxygen (CMRO2) using 15O-labeled H2O, CO, and O2 (16).
These methods are considered as the “gold standard” and are
widely employed, among others, in the study of stroke.
However, these methods are not immediately translatable to
oncology. Tumor metabolism is driven by the rate of glycoly-
sis but without a corresponding increase in aerobic metabolism
(the Warburg effect). In neoplasm, the inability of these tech-
niques to reflect neither ptO2 nor true CMRO2 has led to
the development of various other PET tracers better adapted
to this end. Two classes of radiotracers are employed: the
62/64Cu labeled-diacetyl-bis(N4-methylthiosemicarbazone) and
18F-labeled nitroimidazoles analogs, discussed as follows.
Cu-Diacetyl-bis(N4-Methylthiosemicarbazone)
([64Cu] or [62Cu]-ATSM)
[62/64Cu]-ATSM has been promoted, not as an oxygen sensor, but
as a hypoxia biomarker. Cu(II)-ATSM is reduced to an unsta-
ble Cu(I)-ATSM and then re-oxidized if oxygen is present but
otherwise becomes trapped in hypoxic cells. This radiotracer has
the capability to characterize moderate hypoxia with an enhanced
uptake observed when ptO2 is <35mmHg (17). The long half-life
of [64CU]-ATSM (12.7 h) is an advantage because production and
transport would not only permit utilization in different clinical
research centers but also a limitation in terms of radioprotection
and the impossibility to repeat the measure more than once a
week.With respect to neurooncology, Tateishi and colleagues (18)
examined the interest of using [62Cu]-ATSM for glioma grading
and correlated [62Cu]-ATSM uptake with HIF-1α expression in
glioma patients. However, several studies have suspected a non-
specificity of this radiotracer in hypoxia with an absence of cor-
relation between the spatial distribution of [64Cu]-ATSM uptake
immunohistochemical characterization of hypoxia (19).
Fluorinated Nitroimidazole Compounds
Nitroimidazoles enter viable cells by passive diffusion where they
undergo an active reduction. Under normoxic conditions, these
molecules are re-oxidized and diffuse out of the cell. By contrast,
in severe hypoxia, they eventually become irreversibly trapped
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in the cell at a threshold ptO2 <10mmHg. Several nitroimida-
zole radiotracers are at various stages of preclinical and clinical
development.
[18F]-Fluoromisonidazole ([18F]-FMISO)
Highly selective for hypoxia, [18F]-FMISO is the lead candidate
to assess hypoxia with PET and is the most extensively studied
radiotracer in clinical investigations. In high-grade glioma, where
the ptO2 in the tumor is remarkably low (around 7mmHg), [18F]-
FMISO is increasingly used to estimate hypoxia (20). In our group,
we have shown the ability of [18F]-FMISO to discriminate various
states of hypoxia in different GBMmodels (21, 22). Others studies
have shown that the uptake of [18F]-FMISO is inversely correlated
to overall survival in GBM patients (23). The major limitation of
this approach is the low sensitivity to moderate hypoxia (between
10 and 30mmHg). The second limitation of this radiotracer is its
relative long washout in non-hypoxic cells to obtain an optimal
contrast (between 2 and 4 h after tracer injection).
Other Hydrophilic Tracers
[18F]-Fluoroazomycin-Arabinoside ([18F]-FAZA),
[18F]-Flortanidazole ([18F]-HX4) and
[18F]-Fluoroerythronitroimidazole ([18F]-FETNIM),
1-[2-[18F] Fluoro-1-(Hydroxymethyl)-
Ethoxy]Methyl-2-Nitroimidazole ([18F]-RP-170)
These tracers ([18F]-Fluoroazomycin-arabinoside ([18F]-FAZA),
[18F]-Flortanidazole ([18F]-HX4), and [18F]-fluoroerythronitro
imidazole ([18F]-FETNIM), 1-[2-[18F] Fluoro-1-(hydroxyme
thyl)-ethoxy]methyl-2-nitroimidazole ([18F]-RP-170) because of
their hydrophilic character, have a more rapid plasma half-life
and rapid clearance from tissues than [18F]-FMISO. [18F]-FAZA
has been used to determine hypoxia in models of gliomas and
discriminated clusters of hypoxia and necrosis (24). [18F]-FAZA
awaits clinical investigation for GBM patients. In glioma patients,
[18F]-RP-170was compared to ptO2 andHIF-1α immunostaining
and a selectivity of this tracer for hypoxia was observed (25).
However, regarding their highly hydrophilic properties, these
radiotracers are not recommended the study of brain tumors
because their uptake will be largely influenced by BBB disruption
(26).
2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-penta-
fluoropropyl)-acetamide ([18F]-EF5)
In contradistinction to the hydrophilic tracers, a lipophilic radio-
tracer, [18F]-EF5, has been studied to detect hypoxia in human
GBM. Initially, it was used for immunohistochemistry, [18F]-EF5
possesses a sensitivity near to that of immunohistochemistry but
the synthesis seems problematic (27).
Interest of PET Tracers in the Management
of GBM Patients
The conventional treatment of GBM is surgical resection when
possible, followed by radiotherapy along with concomitant
chemotherapy. Despite these treatment protocols, the median
survival fails to exceed 15months. Imaging of hypoxia should
ameliorate patient management in various ways (see Figure 1).
Optimization of Conventional Treatments
In the therapeutic management of glioma patients, it has been
proposed to use imaging biomarkers of hypoxia to adapt the
treatment according to hypoxic status (20). [18F]-FMISO seems
particularly suited for the modulation of radiation dose in GBM
because the range of ptO2 identified by [18F]-FMISO (from 0
to 10mmHg) corresponds to the scale used to define the radia-
tion dose adapted for hypoxic, radioresistant tumors (28). Hence,
authors have advanced the use of the spatial information derived
from [18F]-FMISO to compute the prescription for the radiation
dose (29). The aim of dose escalation is (i) to increase the efficacy
of treatment in hypoxic area, (ii) to compensate for the spatial
heterogeneity, and (iii) to reduce the toxicity to healthy tissue.
While a boost of radiotherapy in the most hypoxic areas appears
attractive, this concept still requires validation.
Treatment Orientation
Glioblastoma is densely vascularized tumors and, therefore,
targeted anti-angiogenic therapies, such as bevacizumab, (a
humanized monoclonal antibody raised against VEGF), has been
suggested, although recent phase III trials demonstrated disap-
pointing results. An explanation for the failure could be that
no patient selection was performed prior to the initiation of
the treatment. PET-based imaging of hypoxia could be per-
formed before treatment to stratify eligible patients for the anti-
angiogenic strategy. After selection by markers of hypoxia, the
use of radiosensitizers has also been proposed for head and neck
cancers (EORCT trail 1219), an approach that could be applied
to GBM patients. Our group has also demonstrated that hypoxia-
inducible genes, such as erythropoietin, are involved in GBM
growth and resistance to treatment (5). Grounded on hypoxia
imaging, such proteins would represent novel and original targets
for therapy.
Assessment of Treatment Effects
The interest in anti-VEGF therapies has been rekindled since
the emergence of the concept of “normalization.” Anti-angiogenic
treatments are nowplanned to transiently improve tumor vascula-
ture, resulting in increased tumor perfusion and oxygenation. In a
preclinical study in GBM, we have shown that sunitinib treatment
decreases [18F]-FMISO uptake hypothetically due to vascular nor-
malization (21). Similarly, Titz and colleagues (30) have proposed
to program a model of responsivity to anti-angiogenic treatments
from PET imaging of hypoxia in patients.
Conclusion
It is widely accepted that hypoxia is important not only in tumor
growth but also in response to various therapeutic regimens.
The characterization of oxygenation by non-invasive imaging
remains a challenge for the management and adaptation of con-
ventional treatments (radio- and chemotherapy) as well as to
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follow the efficacy of treatment. Several attempts have been made
to develop methods to measure and image tumor oxygen tensions
in vivo without consuming oxygen and thus without exacerbating
the degree of hypoxia. Various approaches have been proposed
to evaluate brain oxygenation at different scales from vascular
to molecular levels. In this review, we argue that, despite devel-
opment of several other methods (summarized Table 1), PET
imaging (especially with fluorinated nitroimidazole compounds)
seems to be, until now, the most relevant tool to characterize
hypoxia in GBM.
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